- 11:24 PM Student visa applications to US, UK see 25% drop
- 10:46 PM Astec LifeSciences to start a project in Q3FY11
- 10:20 PM Rangebound session for Nifty ahead of Nov series e...
- 09:30 PM Politics stirs over Ayodhya mosque report
- 09:23 PM Clean energy, better homes cut pollution, save liv...
- 09:11 PM US to face stimulus aftershocks: Warren Buffett
- 09:02 PM Expert stock/sector picks for tricky markets
- 08:53 PM Indian techie logging out of downturn gloom
- 08:52 PM Expert stock/sector picks in these markets
- 08:44 PM Govt not to relook at arrested CLB member's probe



Treatment for obesity traditionally involves diet therapy and lifestyle modifications such as physical exercise. However, conventional therapies alone are not always sufficient in achieving desired weight loss, as they have their own limitations. The decreased food intake may lead to nutritional deficiencies and the obese may find it difficult to strictly follow the diet regimen. Hence these difficulties in long-term weight management are encouraging patients to look for more effective treatment options with guaranteed results.
Emerging anti-obesity treatment therapies such as pharmacotherapy, bariatric surgeries, as well as the use of weight loss devices will help meet the rising need to reduce the prevalence of obesity and its associated health risks.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis on Clinical Management of Obesity, then send an e-mail to Shwetha Thomas/ Samantha Unnikrishnan, Corporate Communications, at sthomas@frost.com / sunnikrishnan@frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the overview by e-mail upon receipt of the above information.
“Pharmacotherapy, is an Food and Drug Administration (FDA) approved treatment for patients who have not responded to diet therapy and physical exercises,” states Frost & Sullivan Research Analyst Sangeetha Prabakar. “It is recommended, both, for obese individuals with a body mass index (BMI) of 30+ who do not have any associated health risks such as type 2 diabetes, heart disease, hypertension, and stroke in addition to moderately obese patients with two or more collateral conditions.”
Contd on page 2....
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Ex-bonus, RIL will see correction: SP Tulsian

- Mkts to remain strong; bet on midcaps: Ramesh Damani
- Sudarshan Sukhani's top five picks for today's trade

- Nifty to test 5500 post 5-7% correction: JM Financial

- Ganeshaspeaks: Market prediction for Nov 25
- Expert sector picks to power your portfolio ahead

- Below Rs 94, Mahindra Satyam can test Rs 85: Bhambwani

- Mah Satyam looks at out-of-court settlement with creditors

- S&P raises fears over health of some banks
Source: ft.com
- Auto sector growth to push up demand for rubber
Source: Business Line
- High networth individuals see glitter in commodities
Source: Business Line
- Tatas may launch electric Indica by early 2011
Source: Business Line










